Craig Hallum Boosts Delcath Systems (NASDAQ:DCTH) Price Target to $21.00

Delcath Systems (NASDAQ:DCTH) had its target price lifted by Craig Hallum from $18.00 to $21.00 in a report released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages also recently weighed in on DCTH. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of Delcath Systems in a research note on Tuesday. StockNews.com raised Delcath Systems from a “sell” rating to a “hold” rating in a report on Friday, October 25th. Stephens reiterated a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $21.00 target price on shares of Delcath Systems in a research report on Friday, October 18th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.25.

Delcath Systems Stock Performance

Shares of NASDAQ:DCTH opened at $14.31 on Friday. The business has a fifty day moving average of $11.42 and a 200-day moving average of $9.88. Delcath Systems has a twelve month low of $3.70 and a twelve month high of $14.47. The firm has a market cap of $457.55 million, a PE ratio of -10.60 and a beta of 0.87.

Institutional Trading of Delcath Systems

Several institutional investors and hedge funds have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Delcath Systems in the 3rd quarter worth $102,000. Barclays PLC bought a new position in Delcath Systems during the third quarter worth about $104,000. Jane Street Group LLC acquired a new position in shares of Delcath Systems during the 3rd quarter worth about $110,000. Riverwater Partners LLC bought a new stake in shares of Delcath Systems in the 3rd quarter valued at about $161,000. Finally, Virtu Financial LLC acquired a new stake in shares of Delcath Systems in the 3rd quarter valued at approximately $289,000. Institutional investors own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.